ArticlePloS one2026
Time to treatment failure and its predictors among children receiving first-line antiretroviral therapy in Tigray Region public general hospitals, North Ethiopia, 2024: Retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric human immunodeficiency virus (HIV) remains a significant public health challenge, with an estimated 1.5 million children living with HIV globally. In addition, first-line antiretroviral therapy (ART) treatment failure has remained high, as studies and reports showed. Furthermore, time to treatment failure and its predictors on first-line ART among HIV-infected children are less researched in the study area after the test-and-treat strategy is implemented. Hence, this study was conducted to assess time to treatment failure and its predictors among children receiving first-line antiretroviral therapy in Tigray Region public general hospitals, North Ethiopia, 2024.
methodsA hospital-based retrospective cohort study was conducted among children who started ART from January 2014 to March 2020 and from February 2023 to August 2023 in Tigray Region public general hospitals. Epi Data version 3.1 and Stata version 14 were used for data entry and analysis, respectively. Kaplan-Meier and log-rank tests were computed. Bivariable analysis variables with p-value < 0.2 were taken to multivariable Cox regression analysis to identify predictors. Finally, 95% CI and p-value <0.05 were considered for statistical significance.
resultsFrom 410 records of children, 55 (13.4%) (95% CI, 10.43-17.08) had treatment failure, with an incidence rate of 3.3 (95% CI, 2.6-4.3) per 1000 child-month observation. The median time to treatment failure was greater than or equal to 75 months. Poor adherence (AHR = 3.6, 95% CI: 1.7-7.5), baseline CD4 count <200 cells/mm3 (AHR = 3.8, 95% CI: 1.8-8.4), baseline CD4 count 201-350 cells/mm3 (AHR = 2.7, 95% CI: 1.2-6.2), and initial Nevirapine-based regimen (AHR = 4, 95% CI: 1.8-8.8) were predictors of time to treatment failure. CONCLUSION AND RECOMMENDATION: The incidence of treatment failure among children receiving first-line ART was found to be high according to the UNAIDS virological suppression targets. Poor adherence, baseline CD4 count, and initial NVP-based regimen were predictors of time to treatment failure of ART. Hence, all children on ART should be closely monitored, mainly on these identified predictors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.